![[ Back to EurekAlert! ]](https://lh3.googleusercontent.com/blogger_img_proxy/AEn0k_tcsBjYzMMMoGaxcr7yYpvaLkTqUkcueTdtO2ZCey2fn2027sBeMPiGNVJkIQFscE-NyfiAMEyeAesC8F6qO3JWOxc_K-TQ8rkiydcjiyI=s0-d){kind=small}
Public release date: 5-Apr-2012[ | E-mail |
Share ] Contact: Irene Kanter-Schlifke
I.Kanter@elsevier.com
31-204-853-359
Elsevier
To be supported by journals Drug Discovery Today and Biosensors & Bioelectronics
Oxford, April 5, 2012 Elsevier, a world-leading provider of scientific, technical and medical information products and services, announces the Label-Free Technologies Conference to be held in Amsterdam, the Netherlands, 1-3 November 2012.
Organized by Elsevier in association with Horiba Scientific, Label-Free Technologies will be a two-day conference entirely dedicated to bringing together the latest research on the advances and application of label-free technology in pharmacology and drug discovery.
The conference, chaired by Professor Evi Kostenis, University of Bonn, Germany and Professor Anthony (Tony) Turner, Linkping University, Sweden, will focus on three themes; state of the art, new applications of currently available instruments and emerging technologies.
"Label-free technologies have made enormous progress in recent years and have generated wealth well beyond the simple sales figures associated with the instruments themselves, by enabling drug development and research in the life sciences. It is now timely to review this emerging subject area and to consolidate the advanced applications now available while looking to the future for what will become available," said conference Co-Chair Professor Turner.
Elsevier's journals Drug Discovery Today and Biosensors & Bioelectronics are the supporting publications for the conference.
Abstracts for oral and poster presentations are invited.
More information including invited speakers available at: http://www.labelfreetech.com
###
About Drug Discovery Today
Drug Discovery Today is one of the most cited review journals in the field of drug discovery. Since its launch in 1996, it continues to publish reviews of key scientific and strategic issues as well as features, such as opinionated Editorials, interviews with international experts and business trends. Drug Discovery Today covers not only the rapid scientific developments in drug discovery associated technologies but also the management, commercial and regulatory issues that increasingly play a part in how R&D is planned, structured and executed.
About Biosensors & Bioelectronics
Biosensors & Bioelectronics is the principal international journal devoted to research, design, development and application of biosensors and bioelectronics. It is an interdisciplinary journal serving professionals with an interest in the exploitation of biological materials and designs in novel diagnostic and electronic devices including sensors, DNA chips, electronic noses, lab-on-a-chip and ?-TAS.
About Horiba Scientific
HORIBA Scientific is one of the world's largest manufacturing organizations of analytical and spectroscopic systems and components, dedicated to scientific research and industry. HORIBA Scientific's expertise in molecular and microanalysis has established itself as the world leader for confocal Raman microscopy, fluorescence microscopy, multiplexed label-free biointeraction platform and XRF. The main fields of application for these advanced technologies are semiconductors, biotechnology, the environment, pharmaceutics, geology and applied fundamental research.
About Elsevier
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include SciVerse ScienceDirect, SciVerse Scopus, Reaxys, MD Consult and Mosby's Nursing Suite, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai's Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
Media contact
Irene Kanter-Schlifke
Elsevier
+31 20 485 3359
I.Kanter@elsevier.com
[ | E-mail | Share ] ?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Public release date: 5-Apr-2012[ | E-mail |
Share ] Contact: Irene Kanter-Schlifke
I.Kanter@elsevier.com
31-204-853-359
Elsevier
To be supported by journals Drug Discovery Today and Biosensors & Bioelectronics
Oxford, April 5, 2012 Elsevier, a world-leading provider of scientific, technical and medical information products and services, announces the Label-Free Technologies Conference to be held in Amsterdam, the Netherlands, 1-3 November 2012.
Organized by Elsevier in association with Horiba Scientific, Label-Free Technologies will be a two-day conference entirely dedicated to bringing together the latest research on the advances and application of label-free technology in pharmacology and drug discovery.
The conference, chaired by Professor Evi Kostenis, University of Bonn, Germany and Professor Anthony (Tony) Turner, Linkping University, Sweden, will focus on three themes; state of the art, new applications of currently available instruments and emerging technologies.
"Label-free technologies have made enormous progress in recent years and have generated wealth well beyond the simple sales figures associated with the instruments themselves, by enabling drug development and research in the life sciences. It is now timely to review this emerging subject area and to consolidate the advanced applications now available while looking to the future for what will become available," said conference Co-Chair Professor Turner.
Elsevier's journals Drug Discovery Today and Biosensors & Bioelectronics are the supporting publications for the conference.
Abstracts for oral and poster presentations are invited.
More information including invited speakers available at: http://www.labelfreetech.com
###
About Drug Discovery Today
Drug Discovery Today is one of the most cited review journals in the field of drug discovery. Since its launch in 1996, it continues to publish reviews of key scientific and strategic issues as well as features, such as opinionated Editorials, interviews with international experts and business trends. Drug Discovery Today covers not only the rapid scientific developments in drug discovery associated technologies but also the management, commercial and regulatory issues that increasingly play a part in how R&D is planned, structured and executed.
About Biosensors & Bioelectronics
Biosensors & Bioelectronics is the principal international journal devoted to research, design, development and application of biosensors and bioelectronics. It is an interdisciplinary journal serving professionals with an interest in the exploitation of biological materials and designs in novel diagnostic and electronic devices including sensors, DNA chips, electronic noses, lab-on-a-chip and ?-TAS.
About Horiba Scientific
HORIBA Scientific is one of the world's largest manufacturing organizations of analytical and spectroscopic systems and components, dedicated to scientific research and industry. HORIBA Scientific's expertise in molecular and microanalysis has established itself as the world leader for confocal Raman microscopy, fluorescence microscopy, multiplexed label-free biointeraction platform and XRF. The main fields of application for these advanced technologies are semiconductors, biotechnology, the environment, pharmaceutics, geology and applied fundamental research.
About Elsevier
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include SciVerse ScienceDirect, SciVerse Scopus, Reaxys, MD Consult and Mosby's Nursing Suite, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai's Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
Media contact
Irene Kanter-Schlifke
Elsevier
+31 20 485 3359
I.Kanter@elsevier.com
[ | E-mail | Share ] ?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
lotto winner jerry lee lewis cesar chavez winning lotto numbers al sharpton giuliana rancic giuliana rancic
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.